^
    15h
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    17h
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    18h
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    19h
    NCI-2020-09704: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2027 --> Jun 2026
    Trial completion date
    |
    Xpovio (selinexor)
    24h
    DALY II Japan/MB-CART2019.1 for DLBCL (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Miltenyi Biomedicine GmbH
    New P2 trial
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    1d
    Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    1d
    A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=43, Suspended, SymBio Pharmaceuticals | Recruiting --> Suspended
    Trial suspension
    2d
    Phase I Study of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=110, Recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P1 trial
    2d
    Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Dec 2026 | Initiation date: Oct 2025 --> Jun 2025 | Trial primary completion date: Feb 2026 --> Nov 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    2d
    Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    New P1 trial
    2d
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=150, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • rocbrutinib (LP-168)
    2d
    Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids Clinical Manifestations in Children Versus Adults. (PubMed, Pediatr Neurol)
    In order to optimize treatment and follow-up, future diagnostic approaches of C.L.I.P.P.E.R.S. in children should include workup for a primary disease such as EBV B cell lymphoma or hemophagocytic lymphohistiocytosis.
    Review • Journal
    |
    PRF1 (Perforin 1)